Kevan R Polkinghorne

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7109551/publications.pdf

Version: 2024-02-01

209 papers	9,989 citations	46984 47 h-index	42364 92 g-index
211 all docs	211 docs citations	211 times ranked	11894 citing authors

#	Article	IF	Citations
1	A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial. Journal of Vascular Access, 2024, 25, 193-202.	0.5	2
2	Practice patterns and predictors of outpatient care following acute kidney injury in an Australian healthcare setting. Internal Medicine Journal, 2022, 52, 79-88.	0.5	1
3	A co-designed integrated kidney and diabetes model of care improves mortality, glycaemic control and self-care. Nephrology Dialysis Transplantation, 2022, 37, 1472-1481.	0.4	1
4	Long-Term Blood Pressure Variability and Kidney Function in Participants of the ASPREE Trial. American Journal of Hypertension, 2022, 35, 173-181.	1.0	9
5	Dietary habits in Australian, New Zealand and Malaysian patients with end stage kidney failure: A preâ€specified crossâ€sectional study of the FAVOURED trial participants. Journal of Human Nutrition and Dietetics, 2022, 35, 1178-1191.	1.3	0
6	Taking a broader view of the health care needs of people with chronic kidney disease. Medical Journal of Australia, 2022, 216, 137-138.	0.8	1
7	CKD Biomarkers, Cognitive Impairment, and Incident Dementia in an Older Healthy Cohort. Kidney360, 2022, 3, 435-445.	0.9	2
8	Multifaceted intervention to reduce haemodialysis catheter related bloodstream infections: REDUCCTION stepped wedge, cluster randomised trial. BMJ, The, 2022, 377, e069634.	3.0	6
9	Effect of Aspirin on CKD Progression in Older Adults: Secondary Analysis From the ASPREE Randomized Clinical Trial. American Journal of Kidney Diseases, 2022, 80, 810-813.	2.1	2
10	Association of Estimated GFR Calculated Using Race-Free Equations With Kidney Failure and Mortality by Black vs Non-Black Race. JAMA - Journal of the American Medical Association, 2022, 327, 2306.	3.8	28
11	Risk factors for major adverse kidney events in the first year after acute kidney injury. CKJ: Clinical Kidney Journal, 2021, 14, 556-563.	1.4	13
12	The impact of comorbid chronic kidney disease and diabetes on health-related quality-of-life: aÂ12-year community cohort study. Nephrology Dialysis Transplantation, 2021, 36, 1048-1056.	0.4	6
13	Patient-led identification and prioritization of exercise interventions for fatigue on dialysis: a workshop report. CKJ: Clinical Kidney Journal, 2021, 14, 831-839.	1.4	11
14	Long-Term Graft and Patient Outcomes Following Kidney Transplantation in End-Stage Kidney Disease Secondary to Hyperoxaluria. Transplantation Proceedings, 2021, 53, 839-847.	0.3	0
15	Home and facility haemodialysis patients: a comparison of outcomes in a matched cohort. Nephrology Dialysis Transplantation, 2021, 36, 1070-1077.	0.4	2
16	Attitudes and Practices of Australian Nephrologists Toward Implementation of Clinical Genomics. Kidney International Reports, 2021, 6, 272-283.	0.4	28
17	Variability and trends over time and across centres in haemodialysis weekly duration in Australia and New Zealand. Nephrology, 2021, 26, 153-163.	0.7	0
18	Subgroup analysis of the ASPirin in Reducing Events in the Elderly randomized clinical trial suggests aspirin did not improve outcomes in older adults with chronic kidney disease. Kidney International, 2021, 99, 466-474.	2.6	18

#	Article	IF	Citations
19	Risk indices predicting graft use, graft and patient survival in solid pancreas transplantation: a systematic review. BMC Gastroenterology, 2021, 21, 80.	0.8	1
20	Center-Effect of Incident Hemodialysis Vascular Access Use: Analysis of a Bi-national Registry. Kidney360, 2021, 2, 674-683.	0.9	2
21	Results from an International Survey of Donor and Recipient Eligibility for Solid Organ Pancreas Transplantation. Annals of Transplantation, 2021, 26, e930787.	0.5	1
22	Home Versus Facility Dialysis and Mortality in Australia and New Zealand. American Journal of Kidney Diseases, 2021, 78, 826-836.e1.	2.1	10
23	The impact of antineutrophil cytoplasmic antibodyâ€associated vasculitis on employment and work disability in an Australian population. International Journal of Rheumatic Diseases, 2021, 24, 904-911.	0.9	3
24	Donor Predictors of Donor Pancreas Retrieval and Subsequent Solid Pancreas Transplantation in Australia and New Zealand from 2007 to 2016. Transplantation Proceedings, 2021, 53, 2358-2368.	0.3	0
25	Socioâ€economic disparity, access to care and patientâ€relevant outcomes after kidney allograft failure. Transplant International, 2021, 34, 2329-2340.	0.8	2
26	Epidemiology and Outcomes of Acute Kidney Diseases: A Comparative Analysis. American Journal of Nephrology, 2021, 52, 342-350.	1.4	15
27	Relationship Between Urinary Phosphate and All-Cause and Cardiovascular Mortality in a National Population-Based Longitudinal Cohort Study. , 2021, , .		1
28	Effect of centreâ€•and patientâ€related factors on uptake of haemodiafiltration in Australia and New Zealand: A cohort study using ANZDATA. Nephrology, 2020, 25, 63-72.	0.7	5
29	Identifying critically important vascular access outcomes for trials in haemodialysis: an international survey with patients, caregivers and health professionals. Nephrology Dialysis Transplantation, 2020, 35, 657-668.	0.4	22
30	Volume management in haemodialysis patients. Current Opinion in Nephrology and Hypertension, 2020, 29, 663-670.	1.0	4
31	Predictors of Arteriovenous Fistula Failure: A Post Hoc Analysis of the FAVOURED Study. Kidney360, 2020, 1, 1259-1269.	0.9	8
32	Are SGLT2 Inhibitors Safe and Effective in Advanced Diabetic Kidney Disease?. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1694-1695.	2.2	1
33	Initial mycophenolate dose in tacrolimus treated renal transplant recipients, a cohort study comparing leukopaenia, rejection and long-term graft function. Scientific Reports, 2020, 10, 19379.	1.6	9
34	Conversion of Urine Proteinâ€"Creatinine Ratio or Urine Dipstick Protein to Urine Albuminâ€"Creatinine Ratio for Use in Chronic Kidney Disease Screening and Prognosis. Annals of Internal Medicine, 2020, 173, 426-435.	2.0	144
35	A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD). Journal of the American Society of Nephrology: JASN, 2020, 31, 2653-2666.	3.0	52
36	Incorporating kidney disease measures into cardiovascular risk prediction: Development and validation in 9 million adults from 72 datasets. EClinicalMedicine, 2020, 27, 100552.	3.2	50

#	Article	IF	Citations
37	REDUcing the burden of dialysis Catheter ComplicaTIOns: a National approach (REDUCCTION) â€“ design and baseline results. Kidney360, 2020, 1, 746-754.	0.9	8
38	Health-related quality of life among patients with comorbid diabetes and kidney disease attending a codesigned integrated model of care: a longitudinal study. BMJ Open Diabetes Research and Care, 2020, 8, e000842.	1.2	11
39	Blood pressure and volume management in dialysis: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2020, 97, 861-876.	2.6	126
40	Survival in Living Kidney Donors: An Australian and New Zealand Cohort Study Using Data Linkage. Transplantation Direct, 2020, 6, e533.	0.8	7
41	Global Dialysis Perspective: Australia. Kidney360, 2020, 1, 48-51.	0.9	11
42	Response to COVID-19 Infection in Hemodialysis Patients: An Australian Perspective. Kidney360, 2020, 1, 829-833.	0.9	1
43	Patient survival on haemodiafiltration and haemodialysis: a cohort study using the Australia and New Zealand Dialysis and Transplant Registry. Nephrology Dialysis Transplantation, 2019, 34, 326-338.	0.4	26
44	The impact of an integrated diabetes and kidney service on patients, primary and specialist health professionals in Australia: A qualitative study. PLoS ONE, 2019, 14, e0219685.	1.1	11
45	Prevalence of chronic kidney disease in the elderly using the ASPirin in Reducing Events in the Elderly study cohort. Nephrology, 2019, 24, 1248-1256.	0.7	12
46	Arteriovenous access practices in Australian and New Zealand dialysis units. Journal of Vascular Access, 2019, 20, 740-745.	0.5	4
47	ESKD or Cancer: Given the Choice, Which Would You Rather Have?. American Journal of Kidney Diseases, 2019, 73, 753-755.	2.1	5
48	Changes in Body Mass Index and Rates of Death and Transplant in Hemodialysis Patients. Epidemiology, 2019, 30, 38-47.	1.2	10
49	Fish oil and aspirin effects on arteriovenous fistula function: Secondary outcomes of the randomised omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) trial. PLoS ONE, 2019, 14, e0213274.	1.1	8
50	A simple score can identify kidney transplant recipients at high risk of severe infection over the following 2Âyears. Transplant Infectious Disease, 2019, 21, e13076.	0.7	6
51	Dialysis initiation, modality choice, access, and prescription: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2019, 96, 37-47.	2.6	235
52	The impact of progressive chronic kidney disease on health-related quality-of-life: a 12-year community cohort study. Quality of Life Research, 2019, 28, 2081-2090.	1.5	27
53	Risk Indices in Deceased-donor Organ Allocation for Transplantation: Review From an Australian Perspective. Transplantation, 2019, 103, 875-889.	0.5	5
54	Trends in Incidence of ESKD in People With Type 1 and Type 2 Diabetes in Australia, 2002-2013. American Journal of Kidney Diseases, 2019, 73, 300-308.	2.1	33

#	Article	IF	Citations
55	Long-term risk of adverse outcomes after acute kidney injury: a systematic review and meta-analysis of cohort studies using consensus definitions of exposure. Kidney International, 2019, 95, 160-172.	2.6	277
56	Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies. Lancet Diabetes and Endocrinology,the, 2019, 7, 115-127.	5.5	199
57	Relationship of Estimated GFR and Albuminuria to Concurrent Laboratory Abnormalities: An Individual Participant Data Meta-analysis in a Global Consortium. American Journal of Kidney Diseases, 2019, 73, 206-217.	2.1	49
58	Associations of Chronic Kidney Disease Markers with Cognitive Function: A 12-Year Follow-Up Study. Journal of Alzheimer's Disease, 2019, 70, S19-S30.	1.2	17
59	Patient-reported barriers and outcomes associated with poor glycaemic and blood pressure control in co-morbid diabetes and chronic kidney disease. Journal of Diabetes and Its Complications, 2019, 33, 63-68.	1.2	9
60	Dialysis catheter management practices in Australia and New Zealand. Nephrology, 2019, 24, 827-834.	0.7	9
61	Natural killer cell function predicts severe infection in kidney transplant recipients. American Journal of Transplantation, 2019, 19, 166-177.	2.6	20
62	Biochemical comparison of 8 h haemodialysis and 4 h haemodiafiltration, and two dialysis membranes, in a randomized crossâ€over trial. Nephrology, 2019, 24, 542-549.	0.7	3
63	Scope and Consistency of Outcomes Reported in Randomized Trials Conducted in Adults Receiving Hemodialysis: A Systematic Review. American Journal of Kidney Diseases, 2018, 72, 62-74.	2.1	39
64	Seroresponses and safety of 13â€valent pneumococcal conjugate vaccination in kidney transplant recipients. Transplant Infectious Disease, 2018, 20, e12866.	0.7	22
65	Report of the Standardized Outcomes in Nephrologyâ€"Hemodialysis (SONG-HD) Consensus Workshop on Establishing a Core Outcome Measure forÂHemodialysis Vascular Access. American Journal of Kidney Diseases, 2018, 71, 690-700.	2.1	62
66	Models of care for coâ€morbid diabetes and chronic kidney disease. Nephrology, 2018, 23, 711-717.	0.7	14
67	Omega-3 Polyunsaturated Fatty Acid Supplementation toÂPrevent Arteriovenous Fistula and Graft Failure: AÂSystematic Review and Meta-analysis of RandomizedÂControlled Trials. American Journal of Kidney Diseases, 2018, 72, 50-61.	2.1	13
68	Risk Predictors and Causes of Technique Failure Within the First Year of Peritoneal Dialysis: An Australia and New Zealand Dialysis and Transplant Registry (ANZDATA) Study. American Journal of Kidney Diseases, 2018, 72, 188-197.	2.1	85
69	Endothelial Progenitor Cells and Vascular Health inÂDialysis Patients. Kidney International Reports, 2018, 3, 205-211.	0.4	14
70	The pathogenesis of hemodialysis vascular access failure and systemic therapies for its prevention: Optimism unfulfilled. Seminars in Dialysis, 2018, 31, 244-257.	0.7	45
71	Vascular Access Outcomes Reported in Maintenance Hemodialysis Trials: A Systematic Review. American Journal of Kidney Diseases, 2018, 71, 382-391.	2.1	41
72	Comparing dialysis centre mortality outcomes across Australia and New Zealand: identifying unusually performing centres 2008â€"2013. BMC Health Services Research, 2018, 18, 1007.	0.9	3

#	Article	IF	Citations
73	The stability and variability of serum and plasma fibroblast growth factor-23 levels in a haemodialysis cohort. BMC Nephrology, 2018, 19, 325.	0.8	11
74	Patient reported barriers are associated with low physical and mental well-being in patients with co-morbid diabetes and chronic kidney disease. Health and Quality of Life Outcomes, 2018, 16, 215.	1.0	5
75	Câ€reactive protein levels in acute respiratory exacerbations of cystic fibrosis. Internal Medicine Journal, 2018, 48, 1392-1395.	0.5	3
76	Type 2 diabetes in patients with endâ€stage kidney disease: influence on cardiovascular diseaseâ€related mortality risk. Medical Journal of Australia, 2018, 209, 440-446.	0.8	22
77	FP555EFFECTS OF FISH OIL SUPPLEMENTATION AND ASPIRIN USE ON NEED FOR ARTERIOVENOUS FISTULA INTERVENTIONS AND CENTRAL VENOUS CATHETERS IN PATIENTS REQUIRING HAEMODIALYSIS. Nephrology Dialysis Transplantation, 2018, 33, i227-i227.	0.4	2
78	Cystatin C estimated glomerular filtration rate and allâ€cause and cardiovascular disease mortality risk in the general population: AusDiab study. Nephrology, 2017, 22, 243-250.	0.7	14
79	Updates on baseline characteristics of the omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology, 2017, 22, 823-824.	0.7	3
80	Predicting 6-month mortality risk of patients commencing dialysis treatment for end-stage kidney disease. Nephrology Dialysis Transplantation, 2017, 32, gfw383.	0.4	20
81	Developing a Set of Core Outcomes for Trials in Hemodialysis: An International Delphi Survey. American Journal of Kidney Diseases, 2017, 70, 464-475.	2.1	218
82	Global Cardiovascular and Renal Outcomes of Reduced GFR. Journal of the American Society of Nephrology: JASN, 2017, 28, 2167-2179.	3.0	194
83	Early serum creatinine accurately predicts acute kidney injury post cardiac surgery. BMC Nephrology, 2017, 18, 93.	0.8	15
84	Total volume and composition of fluid intake and mortality in older women: a cohort study. BMJ Open, 2017, 7, e011720.	0.8	10
85	Effect of Fish Oil Supplementation and Aspirin Use on Arteriovenous Fistula Failure in Patients Requiring Hemodialysis. JAMA Internal Medicine, 2017, 177, 184.	2.6	77
86	Factors associated with patient activation in an Australian population with comorbid diabetes and chronic kidney disease: a cross-sectional study. BMJ Open, 2017, 7, e017695.	0.8	38
87	The fragility of significant results underscores the need of larger randomized controlled trials in nephrology. Kidney International, 2017, 92, 1469-1475.	2.6	47
88	The association between patient activation and selfâ€care practices: A crossâ€sectional study of an Australian population with comorbid diabetes and chronic kidney disease. Health Expectations, 2017, 20, 1375-1384.	1.1	51
89	Longâ€term graft survival in patients with chronic antibodyâ€mediated rejection with persistent peritubular capillaritis treated with intravenous immunoglobulin and rituximab. Clinical Transplantation, 2017, 31, e13037.	0.8	11
90	Fatal Dialysis Vascular Access Hemorrhage. American Journal of Kidney Diseases, 2017, 70, 570-575.	2.1	35

#	Article	IF	Citations
91	Establishing Core Outcome Domains in Hemodialysis: Report of the Standardized Outcomes in Nephrologyâ€"Hemodialysis (SONG-HD) Consensus Workshop. American Journal of Kidney Diseases, 2017, 69, 97-107.	2.1	148
92	Low versus high dialysate calcium concentration in alternate night nocturnal hemodialysis: A randomized controlled trial. Hemodialysis International, 2017, 21, 19-28.	0.4	6
93	BK Virus Associated Nephropathy, a Cause of Early Renal Allograft Dysfunction: A Single Centre Study. Kathmandu University Medical Journal, 2017, 13, 140-145.	0.1	0
94	Primary and tertiary health professionalsâ€™ views on the health-care of patients with co-morbid diabetes and chronic kidney disease â€" a qualitative study. BMC Nephrology, 2016, 17, 50.	0.8	17
95	Different faces of <scp>N</scp>ocardia infection in renal transplant recipients. Nephrology, 2016, 21, 254-260.	0.7	8
96	Baseline characteristics of the omegaâ€3 fatty acids (<scp>F</scp>ish oils) and <scp>A</scp>spirin in <scp>V</scp>ascular access <scp>OU</scp>tcomes in <scp>RE</scp>nal <scp>D</scp>isease (<scp>FAVOURED</scp>) study. Nephrology, 2016, 21, 217-228.	0.7	10
97	Dialysis modality, vascular access and mortality in endâ€stage kidney disease: A biâ€national registryâ€based cohort study. Nephrology, 2016, 21, 878-886.	0.7	15
98	Predictors of Transfer to Home Hemodialysis after Peritoneal Dialysis Completion. Peritoneal Dialysis International, 2016, 36, 547-554.	1.1	16
99	Long-term outcomes of end-stage kidney disease for patients with lupus nephritis. Kidney International, 2016, 89, 1337-1345.	2.6	44
100	Can We Predict the Unpredictable after Vascular Access Creation?. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1729-1731.	2.2	6
101	Willingness to Participate in a Randomized Trial Comparing Catheters to Fistulas for Vascular Access in Incident Hemodialysis Patients: An International Survey of Nephrologists. Canadian Journal of Kidney Health and Disease, 2016, 3, 125.	0.6	3
102	Longâ€term outcomes of endâ€stage kidney disease for patients with <scp>IgA</scp> nephropathy: A multiâ€centre registry study. Nephrology, 2016, 21, 387-396.	0.7	8
103	How Can the Complications of Central Vein Catheters Be Reduced?. Seminars in Dialysis, 2016, 29, 197-198.	0.7	1
104	Deferasirox at therapeutic doses is associated with dose-dependent hypercalciuria. Bone, 2016, 85, 55-58.	1.4	25
105	Intensive Hemodialysis and Mortality Risk in Australian andÂNewÂZealand Populations. American Journal of Kidney Diseases, 2016, 67, 617-628.	2.1	42
106	Vascular Access, Mortality, and Home Hemodialysis: Back to the Future. American Journal of Kidney Diseases, 2016, 67, 176-178.	2.1	2
107	Patient and Caregiver Priorities for Outcomes in Hemodialysis: An International Nominal Group Technique Study. American Journal of Kidney Diseases, 2016, 68, 444-454.	2.1	232
108	The Perspectives of Patients on Health-Care for Co-Morbid Diabetes and Chronic Kidney Disease: A Qualitative Study. PLoS ONE, 2016, 11, e0146615.	1.1	40

#	Article	IF	Citations
109	Standardised outcomes in nephrology â€“ Haemodialysis (SONG-HD): study protocol for establishing a core outcome set in haemodialysis. Trials, 2015, 16, 364.	0.7	67
110	Predictors and Outcomes of Transfers from Peritoneal Dialysis to Hemodialysis. Peritoneal Dialysis International, 2015, 35, 306-315.	1.1	29
111	An Incident Cohort Study Comparing Survival on Home Hemodialysis and Peritoneal Dialysis (Australia) Tj ETQq1 1 0.784314 rgBT /Over Nephrology: CJASN, 2015, 10, 1397-1407.	2.2	50
112	Research Priorities in CKD: Report of a National Workshop Conducted in Australia. American Journal of Kidney Diseases, 2015, 66, 212-222.	2.1	73
113	The Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post-initiation trial modifications. BMC Nephrology, 2015, 16, 89.	0.8	21
114	Outcomes of integrated home dialysis care: a multi-centre, multi-national registry study. Nephrology Dialysis Transplantation, 2015, 30, 1897-1904.	0.4	20
115	Clustering and Residual Confounding in the Application of Marginal Structural Models: Dialysis Modality, Vascular Access, and Mortality. American Journal of Epidemiology, 2015, 182, 535-543.	1.6	12
116	Temporal Changes in Mortality Risk by Dialysis Modality in the Australian and New Zealand Dialysis Population. American Journal of Kidney Diseases, 2015, 66, 489-498.	2.1	41
117	<scp>DEBATE</scp>: Should Dialysis at Home be Mandatory for All Suitable <scp>ESRD</scp> Patients?. Seminars in Dialysis, 2015, 28, 147-154.	0.7	7
118	Vitamin D therapy in chronic kidney disease: back to the future?. Clinical Nephrology, 2015, 84 (2015), 65-74.	0.4	5
119	Survival on Home Dialysis in New Zealand. PLoS ONE, 2014, 9, e96847.	1.1	41
120	The Association between Body Mass Index and Mortality in Incident Dialysis Patients. PLoS ONE, 2014, 9, e114897.	1.1	37
121	Elderly patients with CKDâ€"dilemmas in dialysis therapy and vascular access. Nature Reviews Nephrology, 2014, 10, 116-122.	4.1	37
122	Buttonhole Cannulation and Clinical Outcomes in a Home Hemodialysis Cohort and Systematic Review. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 110-119.	2.2	93
123	Arteriovenous Fistula Patency: Some Answers but Questions Remain. American Journal of Kidney Diseases, 2014, 63, 384-386.	2.1	5
124	Defining the relationship between average glucose and HbA1c in patients with type 2 diabetes and chronic kidney disease. Diabetes Research and Clinical Practice, 2014, 104, 84-91.	1.1	24
125	Histopathologic and Clinical Predictors of Kidney Outcomes inÂANCA-Associated Vasculitis. American Journal of Kidney Diseases, 2014, 63, 227-235.	2.1	80
126	Estimated Glomerular Filtration Rate versus Albuminuria in the Assessment of Kidney Function: What's More Important?. Clinical Biochemist Reviews, 2014, 35, 67-73.	3.3	9

#	Article	IF	Citations
127	Cystatin C versus Creatinine in Determining Risk Based on Kidney Function. New England Journal of Medicine, 2013, 369, 932-943.	13.9	729
128	Blood Pressure and Blood Volume: Acute and Chronic Considerations in Hemodialysis. Seminars in Dialysis, 2013, 26, 62-72.	0.7	11
129	Daily Variation in Death in Patients Treated by Long-term Dialysis: Comparison of In-Center Hemodialysis to Peritoneal and Home Hemodialysis. American Journal of Kidney Diseases, 2013, 61, 96-103.	2.1	48
130	Vancomycin-resistant enterococci colonization does not increase mortality in end-stage kidney failure: a caseâ€"control study. Journal of Hospital Infection, 2013, 85, 289-296.	1.4	6
131	Serum 25-Hydroxyvitamin D Deficiency and the 5-Year Incidence of CKD. American Journal of Kidney Diseases, 2013, 62, 58-66.	2.1	45
132	Vascular Access Surveillance: Time to End the Controversy. Seminars in Dialysis, 2013, 26, 257-259.	0.7	8
133	Early pancreas allograft thrombosis. Clinical Transplantation, 2013, 27, 410-416.	0.8	22
134	<scp>KHAâ€CARI</scp> Guideline: Vascular access â€" central venous catheters, arteriovenous fistulae and arteriovenous grafts. Nephrology, 2013, 18, 701-705.	0.7	93
135	Mycophenolate and lower graft function reduce the seroresponse of kidney transplant recipients to pandemic H1N1 vaccination. Kidney International, 2012, 82, 212-219.	2.6	60
136	Comparison of Risk Prediction Using the CKD-EPI Equation and the MDRD Study Equation for Estimated Glomerular Filtration Rate. JAMA - Journal of the American Medical Association, 2012, 307, 1941-51.	3.8	810
137	Water quality in conventional and home haemodialysis. Nature Reviews Nephrology, 2012, 8, 725-734.	4.1	19
138	A Decade After the KDOQI CKD Guidelines: A Perspective From Australia. American Journal of Kidney Diseases, 2012, 60, 725-726.	2.1	3
139	25-hydroxyvitamin D Levels and chronic kidney disease in the AusDiab (Australian Diabetes, Obesity and) Tj ETQq1 1 0.784314 rgBT /Ov	0.8	33
140	Optimal Hemodialysis Vascular Access in the Elderly Patient. Seminars in Dialysis, 2012, 25, 640-648.	0.7	84
141	Chronic kidney disease and automatic reporting of estimated glomerular filtration rate: new developments and revised recommendations. Medical Journal of Australia, 2012, 197, 222-223.	0.8	112
142	Chronic kidney disease and measurement of albuminuria or proteinuria: a position statement. Medical Journal of Australia, 2012, 197, 224-225.	0.8	179
143	Efficacy of patient questionnaire in predicting renal dysfunction in outpatients older than 60â€ƒyears of age prior to contrast-enhanced computed tomography. Journal of Medical Imaging and Radiation Oncology, 2012, 56, 168-172.	0.9	2
144	Association between initial and pretransplant dialysis modality and graft and patient outcomes in live- and deceased-donor renal transplant recipients. Transplant International, 2012, 25, 1032-1040.	0.8	4

#	Article	IF	Citations
145	Secular Trends in Cardiovascular Mortality Rates of Patients Receiving Dialysis Compared With the General Population. American Journal of Kidney Diseases, 2011, 58, 64-72.	2.1	110
146	Physical inactivity and chronic kidney disease in Australian adults: The AusDiab study. Nutrition, Metabolism and Cardiovascular Diseases, 2011, 21, 104-112.	1.1	37
147	Intraâ€dialytic hypotension and blood volume and blood temperature monitoring. Nephrology, 2011, 16, 13-18.	0.7	19
148	Attenuation of aortic calcification with lanthanum carbonate versus calciumâ€based phosphate binders in haemodialysis: A pilot randomized controlled trial. Nephrology, 2011, 16, 290-298.	0.7	109
149	Lateral lumbar Xâ€ray assessment of abdominal aortic calcification in Australian haemodialysis patients. Nephrology, 2011, 16, 389-395.	0.7	25
150	Fibroblast growth factor 23 in chronic kidney disease: New insights and clinical implications. Nephrology, 2011, 16, 261-268.	0.7	17
151	Effect of exercise on albuminuria in people with diabetes. Nephrology, 2011, 16, 704-709.	0.7	13
152	Advanced chronic kidney disease, cardiovascular events and the effect of diabetes: data from the Atherosclerosis and Folic Acid Supplementation Trial. Internal Medicine Journal, 2011, 41, 825-832.	0.5	4
153	Identification of alternatively activated macrophages in newâ€onset paediatric and adult immunoglobulin A nephropathy: potential role in mesangial matrix expansion. Histopathology, 2011, 58, 198-210.	1.6	68
154	Waterâ€soluble vitamin levels in extended hours hemodialysis. Hemodialysis International, 2011, 15, 30-38.	0.4	37
155	Barriers to Timely Arteriovenous Fistula Creation: A Study of Providers and Patients. American Journal of Kidney Diseases, 2011, 57, 873-882.	2.1	76
156	Diagnostic Accuracy of Urine Dipsticks for Detection of Albuminuria in the General Community. American Journal of Kidney Diseases, 2011, 58, 19-28.	2.1	170
157	Home Hemodialysis and Mortality Risk in Australian and New Zealand Populations. American Journal of Kidney Diseases, 2011, 58, 782-793.	2.1	168
158	Reproducibility of Urinary Albumin Assays by Immunonephelometry After Long-term Storage at â^'70Â°C. American Journal of Kidney Diseases, 2011, 58, 685-687.	2.1	2
159	Missing Data and Multiple Imputation When Predicting Mortality in Incident Dialysis Patients. American Journal of Kidney Diseases, 2011, 58, 679.	2.1	1
160	Population Prevalance of Proteinuria and Diagnostic Accuracy of Urine Dipsticks. American Journal of Kidney Diseases, 2011, 58, 1039.	2.1	1
161	High rates of albuminuria but not of low eGFR in Urban Indigenous Australians: the DRUID Study. BMC Public Health, 2011, 11, 346.	1.2	22
162	Longitudinal Body Composition Changes Due to Dialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 1668-1675.	2.2	47

#	Article	IF	Citations
163	Improving CKD-MBD management in haemodialysis patients: barrier analysis for implementing better practice. Nephrology Dialysis Transplantation, 2011, 26, 1319-1326.	0.4	39
164	Controversies in chronic kidney disease staging. Clinical Biochemist Reviews, 2011, 32, 55-9.	3.3	17
165	Comparison of the Prevalence and Mortality Risk of CKD in Australia Using the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) Study GFR Estimating Equations: The AusDiab (Australian Diabetes, Obesity and Lifestyle) Study. American Journal of Kidney Diseases, 2010, 55, 660-670.	2.1	231
166	Effect of Alendronate on Vascular Calcification in CKD Stages 3 and 4: A Pilot Randomized Controlled Trial. American Journal of Kidney Diseases, 2010, 56, 57-68.	2.1	99
167	Using vertebral bone densitometry to determine aortic calcification in patients with chronic kidney disease. Nephrology, 2010, 15, 575-583.	0.7	12
168	JNK signalling in human and experimental renal ischaemia/reperfusion injury. Nephrology Dialysis Transplantation, 2010, 25, 2898-2908.	0.4	42
169	Body composition in home haemodialysis versus conventional haemodialysis: a cross-sectional, matched, comparative study. Nephrology Dialysis Transplantation, 2010, 25, 568-573.	0.4	8
170	Relationship between Dialysis Modality and Mortality. Journal of the American Society of Nephrology: JASN, 2009, 20, 155-163.	3.0	282
171	Determination and Validation of Aortic Calcification Measurement from Lateral Bone Densitometry in Dialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 119-127.	2.2	38
172	Alcohol consumption and 5-year onset of chronic kidney disease: the AusDiab study. Nephrology Dialysis Transplantation, 2009, 24, 2464-2472.	0.4	123
173	Effect of a Vascular Access Nurse Coordinator to Reduce Central Venous Catheter Use in Incident Hemodialysis Patients: A Quality Improvement Report. American Journal of Kidney Diseases, 2009, 53, 99-106.	2.1	71
174	Vascular Access Practice in Hemodialysis: Instrumental in Determining Patient Mortality. American Journal of Kidney Diseases, 2009, 53, 359-362.	2.1	10
175	Preventing AVF thrombosis: the rationale and design of the Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology, 2009, 10, 1.	0.8	58
176	Relationship between vascular calcification, arterial stiffness and bone mineral density in a crossâ€sectional study of prevalent Australian haemodialysis patients. Nephrology, 2009, 14, 105-112.	0.7	35
177	Anthropometric measurements of Australian Aboriginal adults living in remote areas: Comparison with nationally representative findings. American Journal of Human Biology, 2008, 20, 317-324.	0.8	35
178	Impact of intradialytic exercise on arterial compliance and Bâ€type natriuretic peptide levels in hemodialysis patients. Hemodialysis International, 2008, 12, 254-263.	0.4	79
179	Home hemodialysis in Australia: Current perspective. Hemodialysis International, 2008, 12, S6-S10.	0.4	21
180	Are traditional risk factors valid for assessing cardiovascular risk in endâ€stage renal failure patients?. Nephrology, 2008, 13, 667-671.	0.7	20

#	Article	IF	Citations
181	Vascular access surveillance. Nephrology, 2008, 13, S1-11.	0.7	33
182	Pharmacological approaches to preventing vascular access failure. Nephrology, 2008, 13, S12-6.	0.7	7
183	Reduction in Î²2-Microglobulin With Super-flux Versus High-flux Dialysis Membranes: Results of a 6-Week, Randomized, Double-blind, Crossover Trial. American Journal of Kidney Diseases, 2008, 52, 93-101.	2.1	27
184	Predictive Value of Nephelometric and High-Performance Liquid Chromatography Assays of Urine Albumin for Mortality in a High-Risk Aboriginal Population. American Journal of Kidney Diseases, 2008, 52, 672-682.	2.1	17
185	Socioeconomic Disadvantage and Kidney Disease in the United States, Australia, and Thailand. American Journal of Public Health, 2008, 98, 1306-1313.	1.5	45
186	Limited knowledge of kidney disease in a survey of AusDiab study participants. Medical Journal of Australia, 2008, 188, 204-208.	0.8	53
187	Associations between vascular calcification, arterial stiffness and bone mineral density in chronic kidney disease. Nephrology Dialysis Transplantation, 2007, 23, 586-593.	0.4	214
188	HPLC-Detected Albuminuria Predicts Mortality. Journal of the American Society of Nephrology: JASN, 2007, 18, 3171-3176.	3.0	27
189	Quantifying the excess risk for proteinuria, hypertension and diabetes in Australian Aborigines: comparison of profiles in three remote communities in the Northern Territory with those in the AusDiab study. Australian and New Zealand Journal of Public Health, 2007, 31, 177-183.	0.8	43
190	Risk factors for peritoneal dialysis-related peritonitis: Can we reduce the incidence and improve patient selection?. Nephrology, 2007, 12, 239-245.	0.7	53
191	Comparison between different dialysate calcium concentrations in nocturnal hemodialysis. Hemodialysis International, 2007, 11, 217-224.	0.4	15
192	Anemia After Kidney Transplantation Is Not Completely Explained by Reduced Kidney Function. American Journal of Kidney Diseases, 2007, 49, 301-309.	2.1	62
193	Trends in Hemodialysis Vascular Access From the Australia and New Zealand Dialysis and Transplant Registry (ANZDATA) 2000 to 2005. American Journal of Kidney Diseases, 2007, 50, 612-621.	2.1	29
194	Implementing iron management clinical practice guidelines in patients with chronic kidney disease having dialysis. Medical Journal of Australia, 2006, 185, 310-314.	0.8	23
195	Does monthly native arteriovenous fistula blood-flow surveillance detect significant stenosisâ€"a randomized controlled trial. Nephrology Dialysis Transplantation, 2006, 21, 2498-2506.	0.4	74
196	Detection and measurement of urinary protein. Current Opinion in Nephrology and Hypertension, 2006, 15, 625-630.	1.0	32
197	Comparison of biochemical, haematological and volume parameters in two treatment schedules of nocturnal home haemodialysis. Nephrology, 2006, 11, 413-418.	0.7	19
198	ADHERENCE TO GUIDELINES FOR PREVENTION OF POSTSPLENECTOMY SEPSIS. AGE AND SEX ARE RISK FACTORS: A FIVE-YEAR RETROSPECTIVE REVIEW. ANZ Journal of Surgery, 2006, 76, 542-547.	0.3	27

#	Article	IF	Citations
199	Population Prevalence of Albuminuria in the Australian Diabetes, Obesity, and Lifestyle (AusDiab) Study: Immunonephelometry Compared With High-Performance Liquid Chromatography. American Journal of Kidney Diseases, 2006, 47, 604-613.	2.1	38
200	Measurement of vascular calcification using CT fistulograms. Nephrology Dialysis Transplantation, 2006, 22, 484-490.	0.4	14
201	Leukocyte phenotype and function predicts infection risk in renal transplant recipients. Nephrology Dialysis Transplantation, 2005, 20, 2226-2230.	0.4	24
202	Vascular Access and All-Cause Mortality: A Propensity Score Analysis. Journal of the American Society of Nephrology: JASN, 2004, 15, 477-486.	3.0	384
203	Determinants of native arteriovenous fistula blood flow. Nephrology, 2004, 9, 205-211.	0.7	14
204	Time and exercise improve phosphate removal in hemodialysis patients. American Journal of Kidney Diseases, 2004, 43, 85-89.	2.1	110
205	Vascular access practice patterns in the New Zealand hemodialysis population. American Journal of Kidney Diseases, 2004, 43, 696-704.	2.1	23
206	Native arteriovenous fistula blood flow and resistance during hemodialysis. American Journal of Kidney Diseases, 2003, 41, 132-139.	2.1	27
207	Epidemiology of vascular access in the Australian hemodialysis population. Kidney International, 2003, 64, 1893-1902.	2.6	27
208	Predicting vascular access failure: A collective review. Nephrology, 2002, 7, 170-176.	0.7	3
209	Vascular Access for Hemodialysis. , 0, , 460-467.		0